Application of EGFR-TKI in locally advanced non-small cell lung cancer
10.3760/cma.j.issn.1673-422X.2016.04.020
- VernacularTitle:EGFR-TKI在局部晚期非小细胞肺癌中的应用
- Author:
Xia WU
;
Guosheng FENG
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small-cell lung;
Radiotherapy;
Epidermal growth factor receptor tyrosine kinase inhibitor
- From:
Journal of International Oncology
2016;43(4):312-314
- CountryChina
- Language:Chinese
-
Abstract:
With the deepening of the lung cancer molecular biology research,small molecular targets antitumor drugs make breakthrough progress,the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is one of the most attention drug.A series studies show that EGFR-TKI can enhance the antitumor activity of ionizing radiation.Therefore,EGFR-TKI combined with radiotherapy alone for poor-risk patients appears survival benefit,but can't ignore the lung toxicity.However,there is a big contro-versy that EGFR-TKI combined with chemoradiotherapy for locally advanced NSCLC.
